-
Impact of bleeding during dual antiplatelet therapy in patients with coronary artery diseaseY-C Tung, C-T Kuo, C-J Chang et al. -
A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor SignalingBAT Rodriguez, A Bhan, A Beswick et al.
-
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registrySahlén A, Varenhorst C, Lagerqvist B et al.
-
Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical TrialR Mehran, J Chandrasekhar, P Urban et al.
-
Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGYU Baber, R Chandiramani, R Mehran et al.
-
Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral AnticoagulationC Genz, RC Braun-Dullaeus.
-
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of theKedhi E, Fabris E, van der Ent M et al.
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS TrialSS Anand, JW Eikelboom, COMPASS Trial Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
